Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): A trial of the Eastern Cooperative Oncology Group

Cancer

Volumn 112, Issue 12, 2008, Pages 2671-2675

  Dreicer, Robert ^a,f   Li, Hailun ^b   Cooney, Matthew M ^c   Wilding, George ^d   Roth, Bruce J ^e  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^d UNIVERSITY OF WISCONSIN   (United States)

^e VANDERBILT INGRAM CANCER CENTER   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Bladder cancer; Gemcitabine; Pemetrexed disodium; Urothelial cancer

Indexed keywords

GEMCITABINE; PEMETREXED; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BLADDER CANCER; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEHYDRATION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERGLYCEMIA; HYPOTENSION; INFECTION; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REPEATED DRUG DOSE; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; UROGENITAL TRACT CANCER; BLADDER TUMOR; CHEMICALLY INDUCED DISORDER; DISEASE COURSE; MIDDLE AGED; SURVIVAL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; GLUTAMATES; GUANINE; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; SURVIVAL ANALYSIS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 46049110774     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23503     Document Type: Article

References (19)

1. von der Maase H, Hansen S, Roberts J, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18:3068-3077.
2. Roth BJ, Dreicer R, Einhorn LH, et al. Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 1994;12:2264-2270.
3. Sweeney C, Roth B, Kabbinavar F, et al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol. 2006;24:3451-3457.
4. McCaffrey JA, Hilton S, Mazumdar M, et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol. 1997;15:1853-1857.
5. Bamias A, Aravantinos G, Deliveliotis C, et al. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol. 2004;22:220-228.
6. Moore MJ, Tannock IF, Ernst DS, et al. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol. 1997;15:3441-3445.
7. Stadler WM, Kuzel T, Roth B, Raghavan D, Dorr FA. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol. 1997;15:3394-3398.
8. Shih C, Chen VJ, Gossett LS, et al. LY231514, a pyrrolo [2,3-d] pyrimidine-based anti-folate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997;57:1116-1123.
9. Niyikiza C, Baker SD, Seitz DE, et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther. 2002;1:545-552.
10. Paz-Ares L, Tabernero A, Moyano A, et al. A phase II study of the multi-targeted anti-folate MTA (LY231514) in patients with advanced transitional cell carcinoma of the bladder [abstract]. Proc Am Soc Clin Oncol. 1998;17:339. Abstract 1307.
11. Adjei A, Erlichman C, Sloan J, et al. Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. J Clin Oncol. 2000;18:1748-1757.
12. Mey V, Giovannetti E, De Braud F, et al. In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. Br J Cancer. 2006;95:289-297.
13. Smith T, Khatcheressian J, Lyman G, et al. 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187-3205.
14. Bajorin D, Dodd P, Mazumdar M, et al. Long-term survival in metastatic transitional cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999;17:3173-3181.
15. von der Maase H, Sengelov L, Roberts J, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23:4602-4608.
16. Vaughn D, Manola J, Dreicer R, et al. Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology Group. Cancer. 2002;95:1022-1027.
17. Small E, Lew D, Redman B, et al. Southwest Oncology Group study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point. J Clin Oncol. 2000;18:2537-2544.
18. Galsky M, Mironov S, Iasonos A, Scattergood J, Boyle M, Bajorin D. Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest New Drugs. 2007;25:265-270.
19. von der Maase H, Lehmann J, Gravis G, et al. A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium. Ann Oncol. 2006;17:1533-1538.